(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.

Fig. 5. (A) Rig protein binds to DHR3, EcR, ßFTZ-F1, USP and SVP in vitro. In
vitro synthesized 35S-labelled Rig was incubated in a batch assay
with control GST alone (lane 2) or GST fusions to the indicated receptors in
either the presence (+) or absence () of ligand (1 µM muristerone A,
a potent activator of EcR). Bound Rig was resolved by SDS-PAGE and visualized
by autoradiography. Lane 1 depicts 1/5 the amount of input Rig protein, marked
by an arrow. (B) Rig binds in vitro to the FTZ-F1 ligand binding domain (LBD)
in an AF-2-independent manner. In vitro synthesized 35S-labelled
Rig was incubated in a batch assay with control GST alone (lane 2) or GST
fusions to full-length
FTZ-F1 (lane 3), full-length ßFTZ-F1 (lane
4), the ßFTZ-F1 LBD (E region, lane 5) or a mutated ßFTZ-F1 LBD in
which the core of the AF-2 activation domain was deleted (
AF-2, lane
6). Bound Rig was resolved by SDS-PAGE and visualized by autoradiography. Lane
1 depicts 1/5 the amount of input Rig protein, marked by an arrow.